Haleon plc has had a series of events involving its shares. The company has repeatedly executed and advanced its
share buyback program, indicating a strategy to consolidate value. A number of
institutional investors, such as Cambiar investors LLC and BlackRock, have altered their stakes in Haleon. Pfizer has been shedding its shares in Haleon, through multiple offerings, significantly reducing its ownership from 32% to 15%. However, the biotech company has missed its Q3 forecasts due to a stronger pound and has also reported a marginal decline in third-quarter revenue.
GSK also sold its remaining stake in Haleon. Despite these developments, Haleon's stock received an
average recommendation of 'Buy' from brokerages. It is deemed as a cheap pharmaceutical stock to buy by short sellers. Besides, Haleon's
CFO and other executives have acquired shares under the reward plan. Moreover, the company also granted share awards to its new CFO. On the negative side, Goldman Sachs downgraded Haleon stock to 'neutral' citing overvaluation.
Haleon Stocks News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Sat, 02 Nov 2024 12:31:17 GMT -
Rating 7
- Innovation 0
- Information 6
- Rumor 2
